Published in Psychopharmacology (Berl) on April 01, 1995
The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol (2008) 1.11
Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol (1999) 0.82
Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells. PLoS One (2016) 0.75
Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters. Neurotox Res (2015) 0.75
Brine shrimp: a convenient general bioassay for active plant constituents. Planta Med (1982) 6.46
Brine shrimp: a convenient general bioassay for active plant constituents. Planta Med (1982) 3.45
Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs (1987) 1.68
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem (2000) 1.33
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem (1990) 1.14
Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry (1998) 1.11
Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther (1991) 1.11
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem (1996) 1.11
Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J Med Chem (1993) 1.08
Modification and evaluation of the potato disc assay and antitumor screening of euphorbiaceae seeds. J Nat Prod (1983) 1.06
Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol (1986) 1.06
Asymmetric synthesis of psychotomimetic phenylisopropylamines. J Med Chem (1973) 1.06
Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J Med Chem (2001) 1.05
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology (1998) 1.05
D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther (1991) 1.02
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem (1996) 1.02
[125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav (1990) 1.01
Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol (1987) 0.99
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol (1997) 0.99
Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI. Neuropharmacology (1987) 0.98
Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett (1994) 0.98
[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol (1991) 0.98
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem (1998) 0.98
Comparison of biochemical and histochemical techniques for estrogen receptor analyses in mammary carcinoma. Cancer (1980) 0.97
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol (1991) 0.97
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem (1996) 0.96
Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav (1991) 0.95
Social reactivity and D1 dopamine receptors: studies in mice selectively bred for high and low levels of aggression. Neuropsychopharmacology (1994) 0.95
Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem (1982) 0.94
3,3',5'-Tri-O-methylpiceatannol and 4,3',5'-tri-O-methylpiceatannol: improvements over piceatannol in bioactivity. J Nat Prod (1987) 0.94
Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol (1989) 0.94
MDMA transiently alters biogenic amines and metabolites in mouse brain and heart. Pharmacol Biochem Behav (1989) 0.93
Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther (1998) 0.92
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J Med Chem (1995) 0.92
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther (1992) 0.91
Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berl) (1988) 0.91
Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav (1996) 0.91
2,3-Dihydroxy-9-amino-9,10-dihydrophenanthrene, a rigid congener of dopamine and isoapomorphine. J Med Chem (1978) 0.91
Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J Med Chem (1999) 0.91
Distinct recognition of substrates by the human and Drosophila serotonin transporters. J Pharmacol Exp Ther (2003) 0.91
Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs (2001) 0.91
Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand. Brain Res (1989) 0.90
Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG). Psychopharmacology (Berl) (1989) 0.89
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. J Med Chem (1994) 0.88
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. J Med Chem (1999) 0.88
Structural correlation between apomorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens. J Theor Biol (1976) 0.87
D1 dopamine receptors. Int Rev Neurobiol (2001) 0.87
Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse (1995) 0.87
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J Med Chem (1991) 0.87
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology (Berl) (1995) 0.87
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. J Med Chem (1992) 0.87
Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. J Pharmacol Exp Ther (2001) 0.87
LSD and phenethylamine hallucinogens: new structural analogy and implications for receptor geometry. Life Sci (1978) 0.86
Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology (1991) 0.86
Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. J Med Chem (1998) 0.86
Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP). J Pharmacol Exp Ther (1973) 0.86
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem (1997) 0.86
Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients. J Med Chem (1975) 0.85
"Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications. Neuropharmacology (1995) 0.85
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther (1995) 0.84
Dopamine agonist properties of N-alkyl-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines. J Med Chem (1981) 0.84
Effect of beta-alkyl substitution on D-1 dopamine agonist activity: absolute configuration of beta-methyldopamine. J Med Chem (1987) 0.84
Resolution and absolute configuration of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analogue. J Med Chem (1979) 0.84
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem (1986) 0.84
(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. J Pharmacol Exp Ther (1990) 0.82
D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets (2006) 0.82
Native fluorescence and hallucinogenic potency of some amphetamines. Experientia (1971) 0.82
Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol (1995) 0.82
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur J Pharmacol (1991) 0.82
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol (1993) 0.81
Dopamine D1 receptor agonists as antiparkinson drugs. Trends Pharmacol Sci (1998) 0.81
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA). J Med Chem (1998) 0.81
Benzofuran bioisosteres of hallucinogenic tryptamines. J Med Chem (1992) 0.81
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J Med Chem (1994) 0.81
Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology (Berl) (1998) 0.80
Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. Eur J Pharmacol (1990) 0.80
Steric effects of substituents on phenethylamine hallucinogens. 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring. J Med Chem (1979) 0.80
Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology (Berl) (1991) 0.80
5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat. Neuropharmacology (1997) 0.80
5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol (1993) 0.80
Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine. J Pharmacol Exp Ther (1995) 0.80
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. J Med Chem (1995) 0.80
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol (1994) 0.79
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur J Pharmacol (1987) 0.79
Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA. Pharmacol Biochem Behav (1991) 0.79
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J Med Chem (1985) 0.79
Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sci (1977) 0.79
Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol Biochem Behav (1986) 0.79
Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists. Psychopharmacology (Berl) (1995) 0.79
Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol Biochem Behav (1990) 0.79
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue. J Med Chem (1987) 0.78
Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. J Med Chem (1981) 0.78
5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. Eur J Pharmacol (1996) 0.78
Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav (1998) 0.78
D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors. J Neurochem (1991) 0.78
Absolute configuration and psychotomimetic activity. NIDA Res Monogr (1978) 0.78
Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience (2002) 0.78
Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci (1994) 0.78
Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). Eur J Pharmacol (1991) 0.78